Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II erlotinib as first-line therapy in EGFR-mutated NSCLC
jRCT2080221052Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221052.